Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 843-848

  Aziz, Najib ^b   Nishanian, Parunag ^b   Taylor, Jeremy M G ^b   Mitsuyasu, Ronald T ^b   Jacobson, Jeffrey M ^b   Dezube, Bruce J ^b   Lederman, Michael M ^b   Detels, Roger ^b   Fahey, John L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; INTERFERON INDUCTION; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD; BETA 2-MICROGLOBULIN; CD4 LYMPHOCYTE COUNT; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEOPTERIN; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 0032900581     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314673     Document Type: Article

References (37)

1. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384:529-34.
2. Poli F, Fauci AS. Role of cytokines in the pathogenesis of human immunodeficiency virus infection. In: Aggarwal BB, Puri RK, eds. Human cytokines: their role in disease and therapy. Cambridge, MA: Blackwell Science, 1995; 421-50.
3. H2 cytokine in HIV infection. Immunol Rev 1994; 140:73-92.
4. Fahey JL. Cytokines, plasma immune activation markers and clinically relevant surrogate markers in HIV infection. Clin Diagn Lab Immunol 1998; 5:597-603.
5. Tsoukas CM, Bernard NF. Markers predicting progression of human immunodeficiency virus related disease. Clin Microbiol Rev 1994; 7:14-28.
6. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serological markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322:166-72.
7. Fahey JL, Taylor JMG, Manna B, et al. Prognostic significance of plasma markers of immune activation. AIDS 1998; 12:1581-90.
8. Mire-Sluis AR, Gaines-Das R, Thorpe R. Immunoassays for detecting cytokines: what are they really measuring? J Immunol Methods 1995; 186:157-60.
9. Ledur A, Fitting C, David B, Hamberger C, Cavaillon JM. Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J Immunol Methods 1995; 186:171-9.
10. Kapadia S, Torre-Amione G, Mann DL. Pitfalls in measuring cytokines. Ann Intern Med 1994; 121:149-50.
11. Pesce AJ, Michael JG. Artifacts and limitations of enzyme immunoassays. J Immunol Methods 1992; 150:111-9.
12. Bienvenu J, Coulon L, Doche C, et al. Analytical performances of commercial ELISA kits for IL-2, IL-6 and TNFα. A WHO study. Eur Cytokine Netw 1993; 4:447-51.
13. Mire-Sluis AR, Gaines-Das R, Thorpe R, and participants of the collaborative study. Implications for the assay and biological activity of interleukin-8. J Immunol Methods 1997; 200:1-16.
14. Salazar-Gonzalez JF, Martinez-Maza O, Nishanian P, et al. Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection. J Infect Dis 1998; 178:423-30.
15. + T cells prior to AIDS onset. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:162-70.
16. Kaslow RA, Ostow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-8.
17. Dezube BJ, Lederman MM, Spritzler JG, et al. High-dose pentoxifylline in patients with AIDS. Inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis 1995; 171:1628-32.
18. Jacobson JM, Greenspan JS, Spritzler JG. et al. Thalidomide for the treatment of oral aphthous ulcers in patients with HIV infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487-93.
19. Dezube BJ, Lederman MM, Chapman B, et al. The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV) infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. J Infect Dis 1997; 176:807-10.
20. Aziz N, Nishanian P, Fahey JL. Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures. Clin Diagn Lab Immunol 1998; 5:755-61.
21. Huber C, Batchelor JR, Fuchs D, et al. Immune response associated production of neopterin: release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160:310-6.
22. Hofmann B, Bass H, Nishanian P, et al. Different lymphoid cell populations produce varied levels of neopterin, β2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, Interferon-gamma or tumor necrosis factor-alpha. Clin Exp Immunol 1992; 88:548-54.
23. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical immunologic and virologic parameters. J Infect Dis 1994; 169:420-4; erratum 1994; 169:1186-7.
24. Rubin LA, Kurman CC, Fitz ME, Boutin B. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135:3172-7.
25. Bass HZ, Nishanian P, Hardy WD, et al. Immune changes in HIV infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin Immunol Immunopathol 1992; 64:63-70.
26. Plaeger S, Bass HZ, Nishanian P, et al. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Clin Immunol 1999; 90:238-46.
27. Fuchs D, Jager H, Popescu M, et al. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 1990; 26:75-80.
28. Melmed RN, Taylor JMG, Detels R, et al. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr 1989; 2:70-6.
29. Osmond DH, Shiboski S, Bacchetti P, et al. Immune activation markers and AIDS prognosis. AIDS 1991; 5:505-11.
30. Hofmann B, Wang YX, Cumberland WG, et al. Serum β2-microglobulin level increases in HIV-1 infection: relation to seroconversion, CD4 T cell fall, and prognosis. AIDS 1990; 4:207-14.
31. Aziz N, Nishanian P, Matsuyasu R, Detels R, Fahey JL. Variables that aflect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 1999; 6:89-95.
32. Diamondstone LS, Tollerud DJ, Fuchs D, et al. Factors influencing serum neopterin and β2-microglobulin levels in a healthy diverse population. J Clin Immunol 1994; 14:368-74.
33. Petrovsky N, Harrison LC. Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? J Immunol 1997; 158:5163-8.
34. Jones AC, Besley CR, Warner JA, Warner JO. Variations in serum soluble IL-2 receptor concentration. Pediatr Allergy Immunol 1994; 5:230-4.
35. Auzeby A, Bogdan A, Krosi Z, Touitou M. Time-dependence of urinary neopterin, a marker of cellular immune activity. Clin Chem 1988; 34:1866-7.
36. Gudewill S, Pollmacher T, Vedder H, Schreiber W, Fassbender K, Holsboer F. Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci 1992; 242:53-6.
37. Haas DW, Lederman MM, Clough L, et al. Proinflammatory cytokine and HIV RNA levels during early Mycobacterium avium complex bacteremia in advanced AIDS. J Infect Dis 1998; 177:1746-9.